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Introduction
People with schizophrenia have well-documented attentional 
impairments, including inability to ignore irrelevant stimuli 
(Heinrichs and Zakzanis 1998; McGhie and Chapman, 1962; 
Morris et al., 2013). Consequently, Latent Inhibition (LI), a pro-
cess of learning to ignore irrelevant stimuli seen in humans and 
animals, has a long history of application in animal models of the 
disorder (Lubow, 2010). LI is impaired learning of a conditioned 
stimulus (CS)–unconditioned stimulus (US) association in a 
group receiving pre-exposure to that stimulus without reinforce-
ment (pre-exposed, PE), compared with a group without such 
pre-exposure (non-pre-exposed, NPE). Most studies in patients 
with schizophrenia, their relatives and psychometrically defined 
schizotypy find abnormal LI (either inappropriately present or 
absent depending on symptom profile) (Lubow, 2010, though see 
Swerdlow, 2010). Based on pharmacological data in rats, 
Weiner’s ‘two-headed’ model of LI suggests that there are two 
categories of abnormality in LI that are counteracted by antipsy-
chotic drugs: one in which LI is high in controls and disrupted 
(e.g. by psychotomimetic D-amphetamine, called ‘disrupted LI’) 
and one in which it is low in controls and potentiated (e.g. by 
antipsychotics or psychotomimetics such as scopolamine, 
MK801 or ketamine, called ‘persistent LI’) (Weiner, 2003; 
Weiner and Arad, 2009). It has been suggested that disrupted and 
persistent LI reflect different attentional processes: failure to 
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inhibit attention to irrelevant stimuli and failure to switch atten-
tion when previously irrelevant stimuli become relevant, respec-
tively (Weiner and Arad, 2009). Low or no LI is induced 
experimentally in controls by either increasing the number of 
CS–US pairings or decreasing the amount of stimulus pre-expo-
sure (Moser et al., 2000; Weiner, 2003; Weiner and Arad, 2009). 
In humans and rats antipsychotic drugs potentiate low LI induced 
by decreasing pre-exposure (Moser et al., 2000; Weiner and 
Arad, 2009). This is also seen in some (though not all) strains of 
mice, including the C57BL/6 strain used in the present study 
(Lipina and Roder, 2010; Lipina et al., 2005).
Antipsychotic drugs bind to multiple neurotransmitter and 
peptide receptors but it is Drd-2 blockade that correlates signifi-
cantly with clinical potency (Meltzer et al., 1989; Seeman et al., 
1976). As all antipsychotic drugs are dopamine receptor Drd-2 
antagonists it is inferred that these drugs act via Drd-2; however, 
it is still unclear whether they are strictly required for all the 
behavioural effects of antipsychotic drugs. This is an important 
question, as it is Drd-2 antagonism that produces debilitating 
extra-pyramidal side effects in patients, which seriously limit 
compliance (Fleischhacker et al., 1994; Kapur et al., 2000). In 
models of LI disruption it is inferred that Drd-2 is important in 
antipsychotic restoration of abnormal LI (Moser et al., 2000; 
Weiner and Arad, 2009; Weiner, 2003). This is supported by evi-
dence that LI is enhanced in dopamine Drd-2 receptor-deficient 
mice when LI is low in wild-type controls. This reproduces the 
behavioural effect of antipsychotic drugs on one of the LI abnor-
malities described in the ‘two-headed’ model and indirectly sug-
gests a role for Drd-2 in their effects on LI (Bay-Richter et al., 
2009). Recently, we found that haloperidol and clozapine attenu-
ate D-amphetamine disruption of LI in mice lacking Drd-2 recep-
tors, suggesting these drugs do not require Drd-2 to reverse 
D-amphetamine disruption of LI (Bay-Richter et al., 2013). This 
suggests that the specific behavioural effect of antipsychotic 
drugs to moderate D-amphetamine disruption of LI can occur 
without interaction with Drd-2. In the same study using a dis-
rupted LI protocol where LI is present in controls, haloperidol 
appeared to enhance LI in controls but not mice lacking Drd-2 
receptors, though these effects were not statistically supported. 
This might suggest that, in contrast to reversal of D-amphetamine 
disruption, antipsychotic drug effects to enhance LI may be mod-
erated in the absence of Drd-2. In the present study we therefore 
investigated whether antipsychotic drug (haloperidol and clozap-
ine) potentiation of low LI (rendered low in controls by reducing 
stimulus pre-exposure) is moderated in Drd2-/- mice. To investi-
gate the specificity to Drd-2 we investigated haloperidol under 
the same conditions in Dopamine D1 receptor (D1)-deficient mice 
(Drd1-/-).
Materials and methods
Mice
Congenic Drd-1 and Drd-2 lines were used at 10–20 weeks of 
age as described previously (Bay-Richter et al., 2009, 2013). 
Mice were housed 1–4 per cage on a 12 h light: 12 h dark cycle 
(lights on 07:00 hr), controlled temperature (20 ± 2°C) and 
humidity (40–60%), with food ad libitum. Mice were water 
restricted for 23 h per day throughout the experiment with 1 h 
free access to water in their home cages after each experimental 
session. Experiments were carried out in compliance with licence 
authority under the Animals (Scientific Procedures) Act, UK 
1986; UK Home Office Project licence No: 40/2883.
Genotyping
Genotyping was performed by PCR using genomic DNA 
extracted from ear biopsies (Bay-Richter et al., 2009).
Latent inhibition
Latent inhibition was carried out in six identical conditioning 
chambers (Med-Associate Inc., Vermont, USA) described previ-
ously in detail (Bay-Richter et al., 2009, 2013). Briefly, 7 days 
before testing mice were placed on 23 h water restriction. There 
then followed 6 days of lick training where mice drank in the 
chambers for 15 min and the number of licks was recorded. On 
Day 7 (pre-exposure) mice were placed in the chambers with the 
waterspout withdrawn. One group received 40 presentations 
(determined from prior experiments to produce reduced LI in 
controls) of a 5 s 85 dB tone with a 15 s inter-stimulus interval 
(pre-exposed group, PE); a control group of non-pre-exposed 
(NPE) mice were placed in the chambers for an identical period 
of time but received no tone pre-exposure. On Day 8 (condition-
ing) mice were placed in chambers with the waterspout with-
drawn. After 2 min, two tone–footshock pairings were presented. 
Tones were of 5 s duration and followed by a 1 s 0.38 mA foot-
shock with an inter-trial interval of 2.5 min. Mice remained in the 
chamber for 2.5 min following the second shock presentation. On 
Day 16–17 (rebaseline) mice were placed in chambers for 15 min 
and given free access to water to re-establish stable licking; the 
criterion was that mice that did not complete >300 licks continu-
ously did not continue to the test stage (n=1). On Day 18 (Test) 
mice had free access to the waterspout in chambers. Number of 
licks was recorded and time taken to complete licks 80–90 (A) 
and 90–100 (B) recorded. After completion of 90 licks, the tone 
was presented until the mouse reached lick 100 or 600 seconds 
had elapsed. A suppression ratio (SR) was calculated according 
to the formula A/ (A + B) yielding a scale of 0–0.5. Low SR indi-
cates increased suppression of drinking; high SR indicates 
decreased suppression of drinking. LI is seen as higher SR in PE 
versus NPE groups.
Experimental design and statistics
Statistics were performed using SPSS (Version 18, 2009 SPSS 
Inc. Chicago, Illinois, USA). For LI experiments, analysis of vari-
ance (ANOVA) was used. For post hoc comparisons, planned 
comparisons utilized T-tests with Bonferroni correction for α slip-
page. NS indicates not significant. One limitation of the T-test 
approach is that it does not include the error term from the overall 
ANOVA. We therefore in addition used simple main effects tests 
using the error term from the main ANOVA following significant 
three-way interactions and Bonferroni post hoc tests where appro-
priate. Outliers > 1.5 × inter-quartile range were removed prior to 
analysis. [n=5 exp 1; 2 × Wild-Type NPE Clozapine, 1 × Wild-
Type NPE Haloperidol, 1 × Drd2-/- NPE Haloperidol, 1 × Wild-
Type PE vehicle]/[n=4 experiment 2; 1 × Wild-Type NPE Vehicle, 
1 × Wild-Type NPE Haloperidol, 1 × Drd1-/- PE haloperidol, 1 × 
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Figure 1. Haloperidol (Hal) and clozapine (Cloz) enhanced LI relative 
to vehicle controls in Drd–2+/+ but not Drd–2-/- mice. Mean suppression 
ratio (SR) is shown for non-pre-exposed (NPE) and Pre-exposed groups 
(PE). +indicates p<0.05 sig difference from same treatment group in 
Drd–2-/- genotype. *indicates p<0.05 significant difference from NPE 
group same treatment group and genotype. A high SR indicates lower 
suppression a low SR higher suppression.
Wild-Type PE haloperidol]. The experiment in Drd1-/- mice was 
conducted in females, as we have found male Drd1-/- mice do not 
show robust LI (Bay-Richter et al., 2009). Numbers N were, 
experiment 1: 43 (23F, 20M) Drd–2-/- and 44 (22F, 22M) 
Drd–2+/+; experiment 2: 27F Drd–1+/+ and 26F Drd–1-/-. In both 
experiments groups did not differ in time to complete licks 80–90 
(time A); in experiment 1 there was no effect of sex or interaction 
between sex and other variables (all F values < 1).
Drugs and administration
Haloperidol and clozapine (Sigma-Aldrich, Dorset, UK) were dis-
solved in 25 μL glacial acetic acid and buffered to pH 6.5 using 0.1 
mM NaOH prior to final dilution in sterile 0.9% saline to appropri-
ate doses (0.1 mg/kg for haloperidol; 2.5 mg/kg for clozapine), 
with an injection volume of 10 mL/kg; controls received vehicle to 
the same injection volumes. Doses of haloperidol and clozapine 
were maximum doses testable without sedation and based on our 
previous study (Bay-Richter et al., 2013). Mice received two injec-
tions of haloperidol, clozapine or vehicle via intraperitoneal injec-
tion, one injection 30 min before pre-exposure and the second 24 h 
later 30 min before conditioning sessions.
Results
Effect of clozapine and haloperidol on low LI 
in Drd–2+/+ and Drd–2-/- mice
Both clozapine and haloperidol potentiated LI in Drd–2+/+ but not 
in Drd–2-/- (Figure 1(a)). In a three-way ANOVA (pre-exposure × 
drug treatment × genotype) there was a significant effect of pre-
exposure [F(1,70)=60.3, p<0.001] and drug treatment [F(1,70)=7.35, 
p<0.001], and pre-exposure × drug treatment [F(2,70)=6.21, 
p<0.005] and genotype × drug treatment interactions [F(2,70)=4.49, 
p<0.05]. There was a significant effect of drug treatment in 
Drd–2+/+ mice [F(2,34)=24.8, p<0.0001] but not in Drd–2-/- 
[F(2,36)=0.1, NS]. The three-way pre-exposure × genotype × drug 
treatment interaction was significant [F(2,70)=4.2, p<0.05], there-
fore drug, genotype and pre-exposure were analysed separately for 
post hoc comparisons. Vehicle-treated (Veh) Drd–2+/+ mice receiv-
ing a low number of pre-exposures did not show LI [NPE vs. PE 
T10=.24] while clozapine [NPE vs. PE T11=18.8, p<0.0001]- and 
haloperidol [NPE vs. PE T14=5.9, p<0.0001]-treated Drd–2+/+ 
mice do. NPE vs. PE was not significant for any drug groups in 
Drd–2-/- mice following correction, but Veh and Clozapine groups 
had uncorrected p-values of <0.05. Further support for differences 
between genotypes is provided by comparison of drug treated PE 
groups for each genotype; Veh vs. Hal [Drd–2+/+ T12=6.47, 
p<0.001; Drd–2-/- T13=.25, NS]. Veh vs. Clozapine [Drd–2+/+ 
T9=21.3, p<0. 0001; Drd–2-/- T15=.5, NS].
There was a significant effect of drug treatment in PE-Drd–2+/+ 
(F(2,17)=22.4, p<0.0005) but not in the corresponding Drd–2-/- 
group nor either NPE group. Post hoc Bonferroni tests showed 
significant differences between PE-Vehicle-Drd–2+/+ and 
PE-Haloperidol-Drd–2+/+ (p<0.0001) and PE-Vehicle-Drd–2+/+ 
and PE-clozapine-Drd–2+/+ (p<0.0001).
Simple effects tests (Bonferroni adjusted) using the error term 
from the overall ANOVA further support these conclusions. There 
was a significant effect of genotype in saline PE (F(1,70)=4.68, 
p<0.05), haloperidol PE (F(1.70)=4.98, p<0.05)and clozapine PE 
(F(1,70)=9.45, p<0.005) groups but not in any of the corresponding 
NPE groups. There was a significant effect of drug in Drd–2+/+ PE 
(F(2,71)=16.38, p<0.0001) but not in NPE nor either NPE or PE 
groups in Drd–2-/-. There was a significant effect of pre-exposure 
Figure 2. Haloperidol (Hal) enhanced LI in both Drd–2+/+ and Drd–2-/- 
mice. Mean suppression ratio (SR) is shown for non-pre-exposed (NPE) 
and Pre-exposed groups (PE). *indicates p<0.01 significant difference 
from NPE group same treatment group and genotype. A high SR 
indicates lower suppression a low SR higher suppression.
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(i.e. LI) in Veh-Drd–2-/- (F(1,70)=5.6, p<0.0.001) but not Veh-
Drd–2+/+ (F<1) and in all other groups Haloperidol-Drd–2+/+ 
(F(1,70)=23.8, p<0.0001), Haloperidol-Drd–2-/- (F(1,70)=5.6, 
p<0.05), clozapine-Drd–2-/- (F(1,70)=9.2, p<0.005), clozapine-
Drd–2+/+ (F(1,70)=23.9, p<0.0001).
Effect of haloperidol on low LI (40 PE) in 
Drd1-/- mice
Haloperidol significantly potentiated LI (Figure 2). There was a 
significant effect of genotype [F(1,41)=6.6, p<0.05], Drug treat-
ment [F(1,41)=9.4, p<0.05], pre-exposure [F(1,41)=38.2, p<0.0001] 
and a significant drug treatment × pre-exposure interaction 
[F(1,41)=6.1, p<0.01]. This interaction allowed us to examine the 
effect of drug on NPE and PE separately. There was a significant 
effect of drug treatment in the PE [F(1,23)=8.0, p<0.001] and not 
the NPE [F=.1, NS] group. There was a significant effect of pre-
exposure (i.e. LI) in Haloperidol (F(1,24)=30.4, p<0.0001) but not 
vehicle-treated groups. There was no indication that haloperidol 
induction of LI was moderated in Drd–1-/- mice (drug treatment × 
genotype interaction [F=.22, NS]). NPE vs. PE comparisons 
were significant for Hal-treated groups [Drd–1+/+ T(11)=3.2, 
p<0.01; Drd–1-/- T(10)=15.4, p<0.001] but not vehicle-treated 
groups [Drd–1+/+ T(9)=0.9; Drd–1-/- T(11)=2.0, NS].
Discussion
Clozapine and haloperidol potentiated LI relative to vehicle-
treated controls in Drd–2+/+ mice; Drd–2-/- mice showed similar 
LI whether they received vehicle, haloperidol or clozapine. The 
effects of haloperidol and clozapine on pre-exposure were sig-
nificantly lower in Drd–2-/- compared with Drd–2+/+ controls 
(Figure 1). This suggests that lack of Drd-2 receptors may moder-
ate the effect of these drugs to potentiate LI. Taken in conjunction 
with recent findings that Drd-2 is not necessary for antipsychot-
ics to reverse D-amphetamine disruption of LI (Bay-Richter et 
al., 2013), the present data suggest that antipsychotics can restore 
abnormal LI via either a Drd-2 or a non-Drd-2 mechanism 
depending on how the abnormality is induced.
Drd–2-/- mice showed enhanced LI relative to controls; this 
is consistent with previous experiments in these mice, and 
mimics effects of antipsychotic drugs given alone (Bay-
Richter et al., 2009; Moser et al., 2000). One possible expla-
nation for the failure to observe potentiated LI by antipsychotics 
in Drd–2-/- is that they already show the maximum LI attaina-
ble, and in these conditions further enhancement would nor-
mally no longer be detectable (Bay-Richter et al., 2009). This 
is an unlikely explanation as we observe drug effects in the 
same experiment in Drd–2+/+ to have produced much higher 
PE values, suggesting further enhancement is detectable. 
Furthermore, there is clear dissociation from the effect of halo-
peridol in Drd–1-/- in experiment 2, which is comparable 
between Drd–1+/+ and Drd–1-/- mice.
These data are consistent with theories of schizophrenia that 
suggest antipsychotic drugs act via Drd-2 to modify processes 
that allocate salience based on prior experience (Gray et al., 
1991; Kapur 2003, 2004; Kapur et al., 2005). One possible con-
ceptualisation of antipsychotic drug effects to potentiate LI 
where it is absent in controls, is that they reduce the salience of 
whatever is demanding most attention currently. Where a tone is 
associated with either no consequence or footshock, footshock 
will normally demand attention when the number of pre-expo-
sures is low. In this case, antipsychotic drugs reduce the relative 
salience of the tone–footshock relative to the tone–no conse-
quence association. This is not simply a disruption of the tone–
footshock pairing as NPE groups are unaffected. It has been 
suggested that in patients antipsychotics reduce the salience of 
positive symptoms (Kapur et al., 2005), thus if a particular per-
cept or hallucination were currently demanding the most atten-
tion then it would be predicted that antipsychotics would reduce 
its salience. Theoretical models such as the switching hypothesis 
have proposed explanations of how antipsychotic drugs affect 
these LI phenomena (Weiner and Arad, 2009). These data sug-
gest that Drd-2 antagonism may be important for this salience-
modulating action of the antipsychotic drugs haloperidol and 
clozapine at doses tested, though generalisation to other behav-
ioural models of these processes is merited to assess this more 
specifically. The suggestion that Drd-2 is important is consistent 
with experimental predictions from pharmacological studies of 
LI in rats, mice and humans (Weiner and Arad, 2009; Kumari et 
al., 1999; Moser et al., 2000) but contrasts with effects of these 
drugs in D-amphetamine-disrupted LI which are not Drd-2 
dependent (Bay-Richter et al., 2013). That finding was difficult 
to reconcile with the well-established correlation between affin-
ity for the Drd-2 receptor and clinical efficacy of antipsychotics. 
The present study now shows that lack of Drd-2 can moderate the 
effect of antipsychotics depending on which ‘head’ of the LI 
model is being investigated, ‘disrupted’ or ‘persistent’. This sug-
gests that these antipsychotic drugs may have two behavioural 
actions, one possibly requiring Drd-2 and one not. One behav-
ioural effect is unmasked under conditions of high DA (or other 
neurotransmitter) release following D-amphetamine where LI is 
high in controls and is not Drd-2 dependent (Bay-Richter et al., 
2013), another where LI is low in controls and is moderated in 
the absence of Drd-2.
Drd1-/- mice show a trend towards potentiated LI relative to 
controls, again consistent with our previous findings in female 
mice (Bay-Richter et al., 2009). Haloperidol enhanced LI relative 
to controls in both Drd–1+/+ and Drd–1-/- mice. This suggests that 
lack of Drd–1 does not moderate the effect of haloperidol to 
potentiate low LI. Pharmacological and null mouse studies have 
previously suggested that Drd-1 might play a role in 
D-amphetamine disruption of LI and consequently in the effects 
of antipsychotics to reverse these effects (Bay-Richter et al., 
2013; Nelson et al, 2012). Our findings suggest that this may not 
apply to the potentiation of low LI. Our data are, however, con-
sistent with previous findings that antipsychotic drugs that are 
antagonists at both Drd-1 and Drd-2, reverse D-amphetamine-
disrupted LI and enhance LI when it is low in controls. 
Conversely, selective Drd-1 antagonists reverse amphetamine-
disrupted LI but do not enhance low LI (Trimble et al., 2002). 
This potentially reconciles strong clinical evidence that Drd-2 is 
important for the effects of antipsychotic drugs with arguments 
that Drd-1 antagonism may play a role in the behavioural effects 
of antipsychotics (e.g. Miller, 2009a, 2009b). By necessity the 
Drd-1 experiment was carried out in females; there remains a 
possibility that in males the Drd-1 dependence of haloperidol 
may differ. Because of baseline differences this is not testable 
using this null mouse approach, though experiments in male rats 
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suggest that low LI is not enhanced by selective Drd-1 antago-
nists (Trimble et al, 2002; Nelson et al., 2012).
We have demonstrated that antipsychotic drug potentiation of 
LI is reduced in mice lacking Drd-2. Taken together with previ-
ous findings that antipsychotics can attenuate D-amphetamine 
disruption of LI in mice lacking Drd-2, the data suggest that 
antipsychotic drugs may restore abnormality in learning to ignore 
irrelevant stimuli via either Drd-2 dependent or independent 
mechanisms. Identification of the non-Drd-2 mechanism through 
which antipsychotics specifically modulate salience but not other 
behaviours may help to identify novel non-Drd-2 based therapeu-
tic strategies for psychosis.
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